Webinars

BioProcess International: Ask the Expert Webcast

Protein expression for manufacturing falls into one of two basic categories: stable cell line generation or transient transfection. While stable cell lines provide consistency in product quality and quantity, they are also expensive and time-consuming especially in early discovery and development phases.

In this webinar, a fully-scalable cell engineering technology employing a transient transfection strategy will be discussed. This technology has allowed for the efficient and cost-effective evaluation of vaccine candidates in phase 1 development of an HIV vaccine and has allowed for the therapeutic product to enter into animal studies months ahead of schedule. In addition, custom functional antibody development will be discussed along with the role that media has on antigen folding, expression, and glycosylation for transfection.

Protein expression for manufacturing falls into one of two basic categories: stable cell line generation or transient transfection. While stable cell lines provide consistency in product quality and quantity, they are also expensive and time-consuming especially in early discovery and development phases.

In this webinar, a fully-scalable cell engineering technology employing a transient transfection strategy will be discussed. This technology has allowed for the efficient and cost-effective evaluation of vaccine candidates in phase 1 development of an HIV vaccine and has allowed for the therapeutic product to enter into animal studies months ahead of schedule. In addition, custom functional antibody development will be discussed along with the role that media has on antigen folding, expression, and glycosylation for transfection.

About the Presenter
Victor Ayala, PhD

Dr. Victor Ayala, Senior Staff Scientist, is an Immunologist with ABL, Inc. in Rockville, MD. He serves as a Key Investigator on a several government contracts relating to the manufacture of vaccines in support of Phase I-II clinical trials and as a Primary Investigator for numerous preclinical studies on behalf of industry and academic clients. Dr. Ayala’s expertise spans both the preclinical evaluation of vaccines and therapeutics in animal models plus the refinement of upstream and downstream manufacturing processes used to accelerate timelines and reduce production costs.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo